BAXTER INTERNATIONAL INC

Baxter International Inc. has restructured its operating model, changing its reportable segments from three to two, effective Q2 2026. The new segments are Medical Products & Therapies (MPT) and Healthcare Systems & Technologies (HST), with the former Pharmaceuticals segment now integrated into MPT. The company is furnishing recast historical financial information for comparability, which does not impact previously reported consolidated net income or EPS.

Baxter International Inc. approved a new Executive Severance and Change in Control Plan, effective May 4, 2026, which supersedes the prior plan and expands the definition of "Qualifying Termination." The new plan establishes tiered severance benefits for Vice Presidents and above, including named executive officers, for both non-Change in Control and Change in Control terminations. Additionally, an amendment to CEO Andrew Hider's offer letter was approved, increasing his lump-sum cash payment for medical, dental, or vision coverage from 18 to 24 months in a non-CIC qualifying termination.

Baxter International Inc. reported Q1 2026 net sales of $2.701 billion, a 2.9% increase year-over-year. However, the company posted a net loss attributable to stockholders of $(15) million, or $(0.03) diluted EPS, compared to a net income of $126 million and $0.25 diluted EPS in Q1 2025, primarily due to the prior year's gain from the Kidney Care divestment. Cash flows from continuing operations significantly improved to $213 million. The company also faces ongoing legal and regulatory matters, including Class I recalls for its Novum LVP and multiple lawsuits.

Baxter International Inc. reported first-quarter 2026 sales from continuing operations of $2.7 billion, a 3% increase on a reported basis but a 1% decline organically. Adjusted diluted EPS from continuing operations was $0.36, a 35% decrease year-over-year, impacted by unfavorable comparisons and higher costs. The company reiterated its full-year 2026 financial outlook and declared a quarterly cash dividend of $0.01 per share. Strategic highlights included new product introductions and expansion of its continuous improvement system.